全球范围内,头颈部鳞癌(head and neck squamouscell carcinoma,HNSCC)年发病率超过500 000人,占所有恶性肿瘤发病率的5%。烟草、酒精的滥用以及人乳头瘤病毒(HPV)是HNSCC发病的危险因素;HPV相关的HNSCC具有分化低、基底细胞样特征明显和T分期较低的特点,疗效较好,总体生存率较高。局部复发是HNSCC治疗失败的主要原因,随着局部治疗手段的改进,远处转移的患者也日益增多。仅少部分局部复发的HNSCC患者可以通过手术治疗和放射治疗予以补救,西妥昔单抗(cetuximab,即C225、爱必妥)已经成为复发性/转 Globally, the annual incidence of head and neck squamous cell carcinoma (HNSCC) exceeds 500,000, accounting for 5% of all malignant tumors. Tobacco and alcohol abuse as well as human papillomavirus (HPV) are the risk factors of HNSCC. HPV-associated HNSCC has the characteristics of low differentiation, obvious basal cell-like features and low T staging, and has good curative effect and high overall survival rate . Local recurrence is the main reason for the failure of HNSCC treatment. With the improvement of local treatment, the number of patients with distant metastasis is also increasing. Only a small number of patients with locally recurrent HNSCC can be treated by surgery and radiotherapy to remedy cetuximab (C225, Erbitux) has become a recurrent /